3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
33
Thoracic
29
Genitourinary
14
Head & Neck
13
Dermatologic
12
Gynecologic
9
Breast
8
Other solid neoplasm
2
Lymphoid
2
CNS
2
Conditions
Lymphoma
666
Lymphoma, Non-Hodgkin
593
Leukemia, Lymphocytic, Chronic, B-Cell
535
Precursor Cell Lymphoblastic Leukemia-Lymphoma
485
Lymphoma, Follicular
418
Lymphoma, Large B-Cell, Diffuse
379
Leukemia
358
Hodgkin Disease
354
Lymphoma, Mantle-Cell
306
Leukemia, Myeloid, Acute
250
Multiple Myeloma
237
Myelodysplastic Syndromes
214
Lymphoma, B-Cell, Marginal Zone
196
Recurrence
195
Burkitt Lymphoma
189
Waldenstrom Macroglobulinemia
155
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
130
Lymphoma, B-Cell
127
Neoplasms
118
Lymphoma, T-Cell, Cutaneous
116
Lymphoma, Large-Cell, Anaplastic
113
Hematologic Neoplasms
103
Lymphoma, Large-Cell, Immunoblastic
100
Mycosis Fungoides
95
Myeloproliferative Disorders
94
Sezary Syndrome
86
Lymphoma, T-Cell, Peripheral
83
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
81
Lymphoma, T-Cell
74
Primary Myelofibrosis
70
Interventions
pembrolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Lymphoid
×
Clear all
NCT03010176
2025-10-29
MK-1454-001
Merck Sharp & Dohme LLC
Phase 1
Completed
156 enrolled
20 charts
NCT04317066
2025-04-06
KEYNOTE-A33
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
13 charts